Harvard Medical School is establishing a Transcriptomics and Technology Innovation Platform, which will perform a suite of cutting-edge assays that measure nascent and newly synthesized RNAs (such as Start-seq, PRO-seq, TT-seq). In addition to providing a direct, global read-out of transcription activity, these assays have emerged as optimal strategies for identification of regulatory elements, such as enhancers and lncRNAs. Further, the Platform is designed to enable HMS researchers to continue innovating new technologies, and the Director will play a central role in this process. This new research facility will strive to meet the increasing demand for genomic assays of regulatory elements and gene activity, and is anticipated to have far-reaching benefits, from enabling basic research, to allowing clinicians to better characterize the enhancer landscape in diseased cells and tissues. The Platform will be equipped with automated liquid handling instrumentation that will enable assays to be run in microplate format at relatively high throughput, and on low cell numbers.
This position is ideal for a broadly-trained scientist who is interested in combining aspects of basic biology and medicine, and who is keen to use their skills to contribute to multiple projects in a non-traditional manner. The Director will help develop, optimize and automate new transcriptomic assay methods, with the assistance of the Adelman lab (https://adelman.hms.harvard.edu/), ICCB-Longwood Screening Facility (https://iccb.med.harvard.edu/) and other HMS groups with relevant expertise. They will advise users of the facility as they design experiments and develop, run, and analyze their own transcriptomic assays. The Director will also be responsible for establishing and overseeing workflows within the Platform, for project management and for coordinating equipment maintenance. This position will have a high degree of independence and will appeal to innovative team-players who wish to develop collaborative relationships with HMS investigators that enable both publications and presentations of their work at regional and national scientific symposia and workshops.
Candidates should hold a Ph.D. in molecular biology, biochemistry, cell biology, or a related field, and have experience with a wide variety of biochemistry and molecular biology techniques. Excellent command of written and spoken English is essential, as are strong organizational and interpersonal skills. Direct experience with lab automation and Next Gen sequencing strategies is strongly preferred. This opportunity is ideal for academic or industry candidates who are interested in facilitating academic research relating to pharmacology and drug discovery.
Mabel Duyao, PhD
Contact Email: email@example.com
Equal Opportunity Employer:
We are an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, gender identity, sexual orientation, pregnancy and pregnancy-related conditions or any other characteristic protected by law.
Internal Number: 8315
About Harvard University
Harvard University is devoted to excellence in teaching, learning, and research, and to developing leaders in many disciplines who make a difference globally. The University, which is based in Cambridge and Boston, Massachusetts, has an enrollment of over 20,000 degree candidates, including undergraduate, graduate, and professional students. Harvard has more than 360,000 alumni around the world. The University has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a truly global education. Established in 1636, Harvard is the oldest institution of higher education in the United States.